Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Flow cytometry aneuploidy and cell cycle indexing as a possible tool for differentiating between CD10+ diffuse large B-cell lymphoma and follicular lymphoma.

Azoulay D, Cohen HI, Dementiev E, Eshel E, Akria L, Shaoul E, Horowitz N.

Cytometry B Clin Cytom. 2019 Dec 9. doi: 10.1002/cyto.b.21861. [Epub ahead of print]

PMID:
31816181
2.

BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study.

Zuckerman T, Ram R, Akria L, Koren-Michowitz M, Hoffman R, Henig I, Lavi N, Ofran Y, Horowitz NA, Nudelman O, Tavor S, Yeganeh S, Gengrinovitch S, Flaishon L, Tessler S, Ben Yakar R, Rowe JM.

Blood Adv. 2019 Nov 26;3(22):3740-3749. doi: 10.1182/bloodadvances.2019000468.

3.

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.

Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK; HERCULES Investigators.

N Engl J Med. 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9.

4.

Brain derived neurotropic factor single nucleotide polymorphism Val66Met and serum protein levels are associated with development of vincristine-induced peripheral neuropathy in patients with lymphoma.

Azoulay D, Nasser R, Sharon R, Simanovich L, Akria L, Shaoul E, Horowitz NA.

Br J Haematol. 2019 Apr;185(1):175-177. doi: 10.1111/bjh.15428. Epub 2018 Jun 25. No abstract available.

PMID:
29938784
5.

Elevated serum BDNF levels are associated with favorable outcome in CLL patients: Possible link to CXCR4 downregulation.

Azoulay D, Herishanu Y, Shapiro M, Brandshaft Y, Suriu C, Akria L, Braester A.

Exp Hematol. 2018 Jul;63:17-21.e1. doi: 10.1016/j.exphem.2018.04.005. Epub 2018 Apr 26.

PMID:
29705266
6.

Physicians' lack of knowledge - a possible reason for red blood cell transfusion overuse?

Rahav Koren R, Suriu C, Yakir O, Akria L, Barhoum M, Braester A.

Isr J Health Policy Res. 2017 Dec 12;6(1):49. doi: 10.1186/s13584-017-0173-0.

7.

Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study.

Jurczak W, Moreira I, Kanakasetty GB, Munhoz E, Echeveste MA, Giri P, Castro N, Pereira J, Akria L, Alexeev S, Osmanov E, Zhu P, Alexandrova S, Zubel A, Harlin O, Amersdorffer J.

Lancet Haematol. 2017 Aug;4(8):e350-e361. doi: 10.1016/S2352-3026(17)30106-0. Epub 2017 Jul 14.

PMID:
28712941
8.

Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.

Dann EJ, Bairey O, Bar-Shalom R, Mashiach T, Barzilai E, Kornberg A, Akria L, Tadmor T, Filanovsky K, Abadi U, Kagna O, Ruchlemer R, Abdah-Bortnyak R, Goldschmidt N, Epelbaum R, Horowitz NA, Lavie D, Ben-Yehuda D, Shpilberg O, Paltiel O.

Br J Haematol. 2017 Sep;178(5):709-718. doi: 10.1111/bjh.14734. Epub 2017 Jun 7.

PMID:
28589704
9.

A Puzzling "Switch" in Blood Type Following Blood Transfusion.

Akria L, Chezar J, Zisman-Rozen S, Scheinman EJ, Zonis Z, Hoffmann Y, Falik-Zaccai T, Kalfon L, Weiss M, Braester A, Suriu C, Barhoum M, Kuperman A, Shaoul E.

Ann Lab Med. 2017 May;37(3):293-295. doi: 10.3343/alm.2017.37.3.293. No abstract available.

10.

Hairy cell leukemia-variant without typical morphology and with near-tetraploid DNA content.

Azoulay D, Sonkin V, Akria L, Rozano Gorelick A, Trakhtenbrot L, Hershkovitz D, Shaoul E, Rozen S, Dementiev E, Cohen HI, Suriu C, Braester A.

Cytometry B Clin Cytom. 2018 Jan;94(1):169-171. doi: 10.1002/cyto.b.21503. Epub 2017 Feb 6. No abstract available.

11.

Absolute lymphocyte count as a prognostic marker in newly diagnosed multiple myeloma patients.

Suriu C, Akria L, Azoulay D, Shaoul E, Barhoum M, Braester A.

Int J Lab Hematol. 2016 Jun;38(3):e56-9. doi: 10.1111/ijlh.12482. Epub 2016 Mar 28. No abstract available.

PMID:
27018225
12.

Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome.

Ofran Y, Filanovsky K, Gafter-Gvili A, Vidal L, Aviv A, Gatt ME, Silbershatz I, Herishanu Y, Arad A, Tadmor T, Dally N, Nemets A, Rouvio O, Ronson A, Herzog-Tzarfati K, Akria L, Braester A, Hellmann I, Yeganeh S, Nagler A, Leiba R, Mittelman M, Merkel D.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):e95-9. doi: 10.1016/j.clml.2015.02.030. Epub 2015 Mar 5.

PMID:
25819366
13.

Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma.

Azoulay D, Lavie D, Horowitz N, Suriu C, Gatt ME, Akria L, Perlman R, Braester A, Ben-Yehuda D.

Br J Haematol. 2014 Feb;164(3):454-6. doi: 10.1111/bjh.12624. Epub 2013 Oct 25. No abstract available.

PMID:
24164472
14.

Amyloid tumor behaving as localized amyloidosis in a patient with long history of asymptomatic light chain myeloma.

Akria L, Sonkin V, Altman E, Suriu C, Cohen HI, Braester A.

Isr Med Assoc J. 2013 Jun;15(6):315-6. No abstract available.

15.

Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.

Merkel D, Filanovsky K, Gafter-Gvili A, Vidal L, Aviv A, Gatt ME, Silbershatz I, Herishanu Y, Arad A, Tadmor T, Dally N, Nemets A, Rouvio O, Ronson A, Herzog-Tzarfati K, Akria L, Braester A, Hellmann I, Yeganeh S, Nagler A, Leiba R, Mittelman M, Ofran Y.

Am J Hematol. 2013 Feb;88(2):130-4. doi: 10.1002/ajh.23368.

16.

Rare coexistence of Rosai-Dorfman disease and nodal marginal zone lymphoma complicated by severe life-threatening autoimmune hemolytic anemia.

Akria L, Sonkin V, Braester A, Cohen HI, Suriu C, Polliack A.

Leuk Lymphoma. 2013 Jul;54(7):1553-6. doi: 10.3109/10428194.2012.740564. Epub 2013 Jan 28. Review. No abstract available.

PMID:
23270580
17.

Alemtuzumab and myelodysplasia: a story of love and hate (possible alemtuzumab-induced myelodysplastic changes).

Braester A, Akria L, Suriu C, Sonkin V.

Acta Haematol. 2013;129(3):185-6. doi: 10.1159/000345254. Epub 2012 Dec 19. Review. No abstract available.

PMID:
23257842
18.

Granulocytic sarcoma with pulmonary involvement.

Avraham S, Akria L, Vlodavsky E, Rowe JM.

Am J Hematol. 2007 Mar;82(3):222-3. No abstract available.

19.

A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.

Oren I, Rowe JM, Sprecher H, Tamir A, Benyamini N, Akria L, Gorelik A, Dally N, Zuckerman T, Haddad N, Fineman R, Dann EJ.

Bone Marrow Transplant. 2006 Jul;38(2):127-34. Epub 2006 Jun 5.

PMID:
16751782
20.

A simple approximation for busulfan dose adjustment in adult patients undergoing bone marrow transplantation.

Hoffer E, Akria L, Tabak A, Scherb I, Rowe JM, Krivoy N.

Ther Drug Monit. 2004 Jun;26(3):331-5.

PMID:
15167637

Supplemental Content

Loading ...
Support Center